Clinical Trials Directory
Recruiting
Conditions
Sponsors
Search
About
Trials
/
Sponsors
/ Amgen Research (Munich) GmbH
Amgen Research (Munich) GmbH
Industry · 10 registered clinical trials.
Status
Trial
Phase
Started
Completed
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Diffuse Large B-cell Lymphoma
Phase 2
2012-07-01
Completed
Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acu
Acute Lymphoblastic Leukemia
Phase 1 / Phase 2
2012-01-01
Completed
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Phase 2
2011-12-01
Completed
Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor A
B-cell Acute Lymphoblastic Leukemia
Phase 2
2010-11-01
Completed
Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphobla
B-ALL
Phase 2
2010-10-01
Completed
Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases
Liver Metastases, Colorectal Cancer
Phase 2
2009-03-01
Completed
A Phase 1 Multiple Dose Study to Compare the Effects of AMG 223 and Sevelamer HCL (Renagel®)
Healthy Volunteers
Phase 1
2008-05-01
Completed
Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the
Solid Tumors
Phase 1
2008-03-01
Completed
Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acut
Acute Lymphoblastic Leukemia
Phase 2
2008-01-01
Completed
Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL
Non-Hodgkin's Lymphoma, Relapsed
Phase 1
2004-06-01